Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bio-Thera Starts China Trials of ADC for Solid Tumors

publication date: Jul 13, 2022

Guangzhou Bio-Thera Solutions has begun dosing advanced solid tumor patients in a Phase 1 clinical trial of BAT8006, an antibody drug conjugate (ADC) targeting folic acid receptor α (FRα). BAT8006 uses Bio-Thera's anti-FRα antibody and its ADC linker-payload combination that includes a cleavable linker and a small molecule topoisomerase I inhibitor. BAT8006 is the first candidate from Bio-Thera’s proprietary new ADC platform to start trials. Bio-Thera has six candidates in late-stage clinical trials and has two approved products, plus candidates for immuno-oncology, ADC targeted therapies and autoimmune diseases. More details....

Stock Symbol: (SHA: 688177)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital